Bruker’s revenues for the first quarter of 2016 were $375.4 million, an increase of 6.2 percent compared to revenues of $353.3 million in the first quarter of 2015. Excluding a 1.5 percent net positive effect from acquisitions & divestitures, and a 0.9 percent negative effect from changes in foreign exchange rates, Bruker reported year-over-year organic revenue growth of 5.6 percent for the first quarter of 2016, compared to an organic revenue decline of 3.0 percent in the first quarter of 2015.
“We are pleased to report solid organic revenue growth, operating margin expansion and EPS growth in the first quarter of 2016,” saidFrank Laukien, President & CEO of Bruker. “Our performance was driven by strong revenue and profitability growth in our BioSpin and CALID Groups. In the first quarter of 2016, we achieved the acceptance of our first shielded ultra high-field Aeon™ 1 GHz NMR system ahead of schedule, which contributed to our better than expected financial performance. For the full year 2016, we see a mix of opportunities and demand challenges. We remain committed to our ongoing margin expansion and EPS growth, and our full year 2016 outlook remains unchanged.”